{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:58:31Z","timestamp":1783130311440,"version":"3.54.6"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","award":["242102310117"],"award-info":[{"award-number":["242102310117"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32371309"],"award-info":[{"award-number":["32371309"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017700","name":"Henan Science and Technology Research Project","doi-asserted-by":"crossref","award":["242102310117"],"award-info":[{"award-number":["242102310117"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40259-026-00769-x","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:27:38Z","timestamp":1776068858000},"page":"459-478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Programmed Cell Death Protein 1-Interleukin-2 Bispecific Agents for Cancer Therapy"],"prefix":"10.1007","volume":"40","author":[{"given":"Chang","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingxu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingmin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4086-1441","authenticated-orcid":false,"given":"Eryan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9461-3133","authenticated-orcid":false,"given":"Huicong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"issue":"8","key":"769_CR1","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy:understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807\u201321. https:\/\/doi.org\/10.1038\/s41423-020-0488-6.","journal-title":"Cell Mol Immunol"},{"key":"769_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5825401","volume":"2020","author":"Y Igarashi","year":"2020","unstructured":"Igarashi Y, Sasada T. Cancer vaccines: toward the next breakthrough in cancer immunotherapy. J Immunol Res. 2020;2020:5825401. https:\/\/doi.org\/10.1155\/2020\/5825401.","journal-title":"J Immunol Res"},{"issue":"3","key":"769_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16(3):151\u201367. https:\/\/doi.org\/10.1038\/s41571-018-0142-8.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"769_CR4","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.trecan.2019.05.010","volume":"5","author":"G Szeto","year":"2019","unstructured":"Szeto G, Finley S. Integrative approaches to cancer immunotherapy. Trends Cancer. 2019;5(7):400\u201310. https:\/\/doi.org\/10.1016\/j.trecan.2019.05.010.","journal-title":"Trends Cancer"},{"issue":"11","key":"769_CR5","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1158\/2159-8290.CD-18-0044","volume":"8","author":"B Olson","year":"2018","unstructured":"Olson B, Li Y, Lin Y, Liu ET, Patnaik A. Mouse models for cancer immunotherapy research. Cancer Discov. 2018;8(11):1358\u201365. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0044.","journal-title":"Cancer Discov"},{"key":"769_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223\u201349. https:\/\/doi.org\/10.1146\/annurev-pathol-042020-042741.","journal-title":"Annu Rev Pathol"},{"issue":"12","key":"769_CR7","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/s1470-2045(22)00554-x","volume":"23","author":"R Malmberg","year":"2022","unstructured":"Malmberg R, Zietse M, Dumoulin DW, Hendrikx JJMA, Aerts JGJV, van der Veldt AAM, et al. Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab. Lancet Oncol. 2022;23(12):e552\u201361. https:\/\/doi.org\/10.1016\/s1470-2045(22)00554-x.","journal-title":"Lancet Oncol"},{"issue":"1","key":"769_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41416-018-0294-4","volume":"120","author":"L Hirsch","year":"2018","unstructured":"Hirsch L, Zitvogel L, Eggermont A, Marabelle A. PD-Loma: a cancer entity with a shared sensitivity to the PD-1\/PD-L1 pathway blockade. Br J Cancer. 2018;120(1):3\u20135. https:\/\/doi.org\/10.1038\/s41416-018-0294-4.","journal-title":"Br J Cancer"},{"key":"769_CR9","doi-asserted-by":"publisher","first-page":"175883592093761","DOI":"10.1177\/1758835920937612","volume":"12","author":"B Zhao","year":"2020","unstructured":"Zhao B, Zhao H, Zhao J. Efficacy of PD-1\/PD-L1 blockade monotherapy in clinical trials. Ther Adv Med Oncol. 2020;12:1-12. https:\/\/doi.org\/10.1177\/1758835920937612.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"769_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01123-0","volume":"9","author":"Y Wang","year":"2025","unstructured":"Wang Y, Guo Y, Tan AC, Zhao L, Shi X, Chen Y, et al. A real-world cohort study of immune-related adverse events in patients receiving immune checkpoint inhibitors. NPJ Precis Oncol. 2025;9(1):346. https:\/\/doi.org\/10.1038\/s41698-025-01123-0.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"769_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14733-5","volume":"25","author":"LAM Auch","year":"2025","unstructured":"Auch LAM, Sieber C, Lehnick D, Hug BL. Adverse drug events of immune checkpoint inhibitors\u2014a retrospective, descriptive real-world data analysis. BMC Cancer. 2025;25(1):1303. https:\/\/doi.org\/10.1186\/s12885-025-14733-5.","journal-title":"BMC Cancer"},{"issue":"6","key":"769_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","volume":"24","author":"LH Butterfield","year":"2024","unstructured":"Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol. 2024;24(6):399\u2013416. https:\/\/doi.org\/10.1038\/s41577-023-00973-8.","journal-title":"Nat Rev Immunol"},{"issue":"6717","key":"769_CR13","doi-asserted-by":"publisher","first-page":"eabq7248","DOI":"10.1126\/science.abq7248","volume":"386","author":"A Hayday","year":"2024","unstructured":"Hayday A, Dechanet-Merville J, Rossjohn J, Silva-Santos B. Cancer immunotherapy by \u03b3\u03b4 T cells. Science. 2024;386(6717):eabq7248. https:\/\/doi.org\/10.1126\/science.abq7248.","journal-title":"Science"},{"issue":"23","key":"769_CR14","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","volume":"313","author":"S Rosenberg","year":"1985","unstructured":"Rosenberg S, Lotze M, Muul L, Leitman S, Chang A, Ettinghausen S, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313(23):1485\u201392. https:\/\/doi.org\/10.1056\/NEJM198512053132327.","journal-title":"N Engl J Med"},{"issue":"2","key":"769_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1586\/1744666X.2014.875856","volume":"10","author":"D Skrombolas","year":"2014","unstructured":"Skrombolas D, Frelinger JG. Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy. Expert Rev Clin Immunol. 2014;10(2):207\u201317. https:\/\/doi.org\/10.1586\/1744666X.2014.875856.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"769_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s13046-024-03165-x","volume":"43","author":"K He","year":"2024","unstructured":"He K, Puebla-Osorio N, Barsoumian HB, Sezen D, Rafiq Z, Riad TS, et al. Novel engineered IL-2 nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy. J Exp Clin Cancer Res. 2024;43(1):251. https:\/\/doi.org\/10.1186\/s13046-024-03165-x.","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"769_CR17","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","volume":"192","author":"S Rosenberg","year":"2014","unstructured":"Rosenberg S. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451\u20138. https:\/\/doi.org\/10.4049\/jimmunol.1490019.","journal-title":"J Immunol"},{"issue":"5","key":"769_CR18","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","volume":"14","author":"Y Gu","year":"2024","unstructured":"Gu Y, Wang Z, Wang Y. Bispecific antibody drug conjugates: making 1+1>2. Acta Pharm Sin B. 2024;14(5):1965\u201386. https:\/\/doi.org\/10.1016\/j.apsb.2024.01.009.","journal-title":"Acta Pharm Sin B"},{"issue":"10","key":"769_CR19","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","volume":"10","author":"M Herrera","year":"2024","unstructured":"Herrera M, Pretelli G, Desai J, Garralda E, Siu L, Steiner T, et al. Bispecific antibodies: advancing precision oncology. Trends Cancer. 2024;10(10):893\u2013919. https:\/\/doi.org\/10.1016\/j.trecan.2024.07.002.","journal-title":"Trends Cancer"},{"issue":"8","key":"769_CR20","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585\u2013608. https:\/\/doi.org\/10.1038\/s41573-019-0028-1.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"769_CR21","doi-asserted-by":"publisher","first-page":"2590250","DOI":"10.1080\/19420862.2025.2590250","volume":"17","author":"L Pousse","year":"2025","unstructured":"Pousse L, Manchala A, Klein C, Codarri Deak L. Advanced cytokine-based immunotherapies: targeted cis-delivery strategies for enhanced anti-tumor efficacy and reduced toxicity. MAbs. 2025;17(1):2590250. https:\/\/doi.org\/10.1080\/19420862.2025.2590250.","journal-title":"MAbs"},{"issue":"9","key":"769_CR22","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/s43018-023-00612-0","volume":"4","author":"W Wu","year":"2023","unstructured":"Wu W, Chia T, Lu J, Li X, Guan J, Li Y, et al. IL-2R\u03b1-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells. Nat Cancer. 2023;4(9):1309\u201325. https:\/\/doi.org\/10.1038\/s43018-023-00612-0.","journal-title":"Nat Cancer"},{"issue":"16_suppl","key":"769_CR23","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1200\/JCO.2025.43.16_suppl.8509","volume":"43","author":"J Zhou","year":"2025","unstructured":"Zhou J, Bai X, Chen Y, Liang T, Wang H, Sun Y, et al. First-in-class PD-1\/IL-2 bispecific antibody IBI363 in patients (Pts) with advanced immunotherapy-treated non-small cell lung cancer (NSCLC). J Clin Oncol. 2025;43(16_suppl):8509. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.8509.","journal-title":"J Clin Oncol"},{"issue":"11","key":"769_CR24","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887\u201395. https:\/\/doi.org\/10.1002\/j.1460-2075.1992.tb05481.x.","journal-title":"EMBO J"},{"issue":"18","key":"769_CR25","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis VA, Longo DL. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375(18):1767\u201378. https:\/\/doi.org\/10.1056\/NEJMra1514296.","journal-title":"N Engl J Med"},{"issue":"1","key":"769_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02095-8","volume":"23","author":"Q Liu","year":"2024","unstructured":"Liu Q, Guan Y, Li S. Programmed death receptor (PD-)1\/PD-ligand (L)1 in urological cancers\u202f: the \u201call-around warrior\u201d in immunotherapy. Mol Cancer. 2024;23(1):183. https:\/\/doi.org\/10.1186\/s12943-024-02095-8.","journal-title":"Mol Cancer"},{"issue":"6","key":"769_CR27","doi-asserted-by":"publisher","first-page":"851","DOI":"10.5858\/arpa.2016-0361-RA","volume":"141","author":"J Guan","year":"2017","unstructured":"Guan J, Lim KS, Mekhail T, Chang C-C. Programmed death ligand-1 (PD-L1) expression in the programmed death receptor-1 (PD-1)\/PD-L1 blockade: a key player against various cancers. Arch Pathol Lab Med. 2017;141(6):851\u201361. https:\/\/doi.org\/10.5858\/arpa.2016-0361-RA.","journal-title":"Arch Pathol Lab Med"},{"key":"769_CR28","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"M Keir","year":"2008","unstructured":"Keir M, Butte M, Freeman G, Sharpe A. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704. https:\/\/doi.org\/10.1146\/annurev.immunol.26.021607.090331.","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"769_CR29","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong H, Zhu G, Tamada K, Chen L. B7\u2013H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5(12):1365\u20139. https:\/\/doi.org\/10.1038\/70932.","journal-title":"Nat Med"},{"issue":"6","key":"769_CR30","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Ribas A. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19(6):1189. https:\/\/doi.org\/10.1016\/j.celrep.2017.04.031.","journal-title":"Cell Rep"},{"issue":"3","key":"769_CR31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","volume":"2","author":"Y Latchman","year":"2001","unstructured":"Latchman Y, Wood C, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261\u20138. https:\/\/doi.org\/10.1038\/85330.","journal-title":"Nat Immunol"},{"issue":"1","key":"769_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01027-5","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol. 2021;14(1):10. https:\/\/doi.org\/10.1186\/s13045-020-01027-5.","journal-title":"J Hematol Oncol"},{"key":"769_CR33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","volume":"236","author":"L Francisco","year":"2010","unstructured":"Francisco L, Sage P, Sharpe A. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219\u201342. https:\/\/doi.org\/10.1111\/j.1600-065X.2010.00923.x.","journal-title":"Immunol Rev"},{"issue":"11","key":"769_CR34","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/s41419-020-03140-2","volume":"11","author":"Q Gou","year":"2020","unstructured":"Gou Q, Dong C, Xu H, Khan B, Hou Y. PD-L1 degradation pathway and immunotherapy for cancer. Cell Death Dis. 2020;11(11):955. https:\/\/doi.org\/10.1038\/s41419-020-03140-2.","journal-title":"Cell Death Dis"},{"issue":"12","key":"769_CR35","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.ymthe.2024.09.026","volume":"32","author":"D Lee","year":"2024","unstructured":"Lee D, Cho M, Kim E, Seo Y, Cha J-H. PD-L1: from cancer immunotherapy to therapeutic implications in multiple disorders. Mol Ther. 2024;32(12):4235\u201355. https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.026.","journal-title":"Mol Ther"},{"issue":"1","key":"769_CR36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13046-020-01786-6","volume":"40","author":"W Fang","year":"2021","unstructured":"Fang W, Zhou T, Shi H, Yao M, Zhang D, Qian H, et al. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8. J Exp Clin Cancer Res. 2021;40(1):4. https:\/\/doi.org\/10.1186\/s13046-020-01786-6.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"769_CR37","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1084\/jem.20051776","volume":"203","author":"M Keir","year":"2006","unstructured":"Keir M, Liang S, Guleria I, Latchman Y, Qipo A, Albacker L, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203(4):883\u201395. https:\/\/doi.org\/10.1084\/jem.20051776.","journal-title":"J Exp Med"},{"issue":"6","key":"769_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004400","volume":"10","author":"Y Yamaguchi","year":"2022","unstructured":"Yamaguchi Y, Gibson J, Ou K, Lopez LS, Ng RH, Leggett N, et al. PD-L1 blockade restores CAR T cell activity through IFN-\u03b3-regulation of CD163+ M2 macrophages. J Immunother Cancer. 2022;10(6):e004400. https:\/\/doi.org\/10.1136\/jitc-2021-004400.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"769_CR39","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","volume":"38","author":"F Dammeijer","year":"2020","unstructured":"Dammeijer F, Gulijk MV, Mulder EEAP, Lukkes M, Aerts JG. The PD-1PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes. Cancer Cell. 2020;38(5):685-700.e8. https:\/\/doi.org\/10.1016\/j.ccell.2020.09.001.","journal-title":"Cancer Cell"},{"issue":"14","key":"769_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1090533","volume":"14","author":"PM McCarthy","year":"2023","unstructured":"McCarthy PM, Valdera FA, Smolinsky TR, Adams AM, O\u2019Shea AE, Thomas KK, et al. Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials. Front Immunol. 2023;14(14):1090533. https:\/\/doi.org\/10.3389\/fimmu.2023.1090533.","journal-title":"Front Immunol"},{"issue":"4","key":"769_CR41","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","volume":"18","author":"ST Paijens","year":"2021","unstructured":"Paijens ST, Vledder A, Bruyn MD, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2021;18(4):842\u201359. https:\/\/doi.org\/10.1038\/s41423-020-00565-9.","journal-title":"Cell Mol Immunol"},{"key":"769_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1034\/j.1600-065x.2002.18806.x","volume":"188","author":"DBP Van","year":"2002","unstructured":"Van DBP, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz E, et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev. 2002;188:51\u201364. https:\/\/doi.org\/10.1034\/j.1600-065x.2002.18806.x.","journal-title":"Immunol Rev"},{"key":"769_CR43","doi-asserted-by":"publisher","unstructured":"Xue W, Li W, Zhang T, Li Z, Wang Y, Qiu Y, et al. Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-\u03b3-associated JAK-STAT pathway. Onco Targets Ther. 201912:2079\u20132088. https:\/\/doi.org\/10.2147\/OTT.S187280.","DOI":"10.2147\/OTT.S187280"},{"issue":"2","key":"769_CR44","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","volume":"173","author":"J Chemnitz","year":"2004","unstructured":"Chemnitz J, Parry R, Nichols K, June C, Riley J. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173(2):945\u201354. https:\/\/doi.org\/10.4049\/jimmunol.173.2.945.","journal-title":"J Immunol"},{"key":"769_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22965-9","author":"K Li","year":"2021","unstructured":"Li K, Yuan Z, Lyu J, Ahn E, Davis SJ, Ahmed R, et al. PD-1 suppresses TCR-CD8 cooperativity during T-cell antigen recognition. Nat Commun. 2021. https:\/\/doi.org\/10.1038\/s41467-021-22965-9.","journal-title":"Nat Commun"},{"key":"769_CR46","doi-asserted-by":"publisher","unstructured":"Liu Y, Liu S, Wu C, Huang W, Xu B, Lian S, et al. PD-1-mediated PI3K\/Akt\/mTOR, Caspase 9\/Caspase 3 and ERK pathways are involved in regulating the apoptosis and proliferation of CD4+ and CD8+ T cells during BVDV infection in vitro. Front Immunol. 2020;11(467). https:\/\/doi.org\/10.3389\/fimmu.2020.00467.","DOI":"10.3389\/fimmu.2020.00467"},{"issue":"16","key":"769_CR47","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","volume":"187","author":"LP Andrews","year":"2024","unstructured":"Andrews LP, Butler SC, Cui J, Cillo AR, Cardello C, Liu C, et al. LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-\u03b3-dependent anti-tumor immunity. Cell. 2024;187(16):4355-4372.e22. https:\/\/doi.org\/10.1016\/j.cell.2024.07.016.","journal-title":"Cell"},{"key":"769_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.715234","volume":"12","author":"JS Dolina","year":"2021","unstructured":"Dolina JS, Van Braeckel-Budimir N, Thomas GD, Salek-Ardakani S. CD8+ T cell exhaustion in cancer. Front Immunol. 2021;12:715234. https:\/\/doi.org\/10.3389\/fimmu.2021.715234.","journal-title":"Front Immunol"},{"issue":"11","key":"769_CR49","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/cac2.12486","volume":"43","author":"X Qu","year":"2023","unstructured":"Qu X, Wang Y, Jiang Q, Ren T, Guo C, Hua K, et al. Interactions of indoleamine 2,3-dioxygenase-expressing LAMP3+ dendritic cells with CD4+ regulatory T cells and CD8+ exhausted T cells: synergistically remodeling of the immunosuppressive microenvironment in cervical cancer and therapeutic implications. Cancer Commun (Lond). 2023;43(11):1207\u201328. https:\/\/doi.org\/10.1002\/cac2.12486.","journal-title":"Cancer Commun (Lond)"},{"issue":"9","key":"769_CR50","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/s12276-024-01301-3","volume":"56","author":"SJ Im","year":"2024","unstructured":"Im SJ, Lee K, Ha SJ. Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends. Exp Mol Med. 2024;56(9):1900\u20138. https:\/\/doi.org\/10.1038\/s12276-024-01301-3.","journal-title":"Exp Mol Med"},{"issue":"5751","key":"769_CR51","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1126\/science.1117893","volume":"310","author":"X Wang","year":"2005","unstructured":"Wang X, Rickert M, Garcia KC. Structure of the quaternary complex of interleukin-2 with its \u03b1, and \u03b3c receptors. Science. 2005;310(5751):1159\u201363. https:\/\/doi.org\/10.1126\/science.1117893.","journal-title":"Science"},{"issue":"1","key":"769_CR52","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/0092-8674(93)90152-g","volume":"73","author":"T Taniguchi","year":"1993","unstructured":"Taniguchi T, Minami Y. The IL-2\/IL-2 receptor system: a current overview. Cell. 1993;73(1):5\u20138. https:\/\/doi.org\/10.1016\/0092-8674(93)90152-g.","journal-title":"Cell"},{"issue":"4","key":"769_CR53","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.cytogfr.2014.07.018","volume":"25","author":"G Sim","year":"2014","unstructured":"Sim G, Radvanyi L. The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev. 2014;25(4):377\u201390. https:\/\/doi.org\/10.1016\/j.cytogfr.2014.07.018.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"10","key":"769_CR54","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","volume":"18","author":"R Spolski","year":"2018","unstructured":"Spolski R, Li P, Leonard WJ. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat Rev Immunol. 2018;18(10):648\u201359. https:\/\/doi.org\/10.1038\/s41577-018-0046-y.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"769_CR55","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3109\/07357909109032798","volume":"9","author":"J Sosman","year":"1991","unstructured":"Sosman J, Hank J, Moore K, Borchert A, Schell K, Kohler P, et al. Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinom. Cancer Investig. 1991;9(1):35\u201348. https:\/\/doi.org\/10.3109\/07357909109032798.","journal-title":"Cancer Investig"},{"issue":"4","key":"769_CR56","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M","volume":"83","author":"US Kammula","year":"1998","unstructured":"Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin\u20102 administration in patients with metastatic cancer. Cancer. 1998;83(4):797\u2013805.","journal-title":"Cancer"},{"issue":"5","key":"769_CR57","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2165\/00063030-199707050-00007","volume":"7","author":"S Noble","year":"1997","unstructured":"Noble S, Goa K. Aldesleukin (recombinant interleukin-2). BioDrugs. 1997;7(5):394\u2013422. https:\/\/doi.org\/10.2165\/00063030-199707050-00007.","journal-title":"BioDrugs"},{"issue":"12","key":"769_CR58","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1080\/14740338.2017.1382472","volume":"16","author":"S Marabondo","year":"2017","unstructured":"Marabondo S, Kaufman HL. High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions. Expert Opin Drug Saf. 2017;16(12):1347\u201357. https:\/\/doi.org\/10.1080\/14740338.2017.1382472.","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"769_CR59","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.4049\/jimmunol.0900080","volume":"182","author":"S Chikuma","year":"2009","unstructured":"Chikuma S, Terawaki S, Hayashi T, Nabeshima R, Yoshida T, Shibayama S, et al. PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo. J Immunol. 2009;182(11):6682\u20139. https:\/\/doi.org\/10.4049\/jimmunol.0900080.","journal-title":"J Immunol"},{"issue":"7930","key":"769_CR60","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","volume":"610","author":"M Hashimoto","year":"2022","unstructured":"Hashimoto M, Araki K, Cardenas MA, Li P, Jadhav RR, Kissick HT, et al. PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program. Nature. 2022;610(7930):173\u201381. https:\/\/doi.org\/10.1038\/s41586-022-05257-0.","journal-title":"Nature"},{"issue":"3","key":"769_CR61","doi-asserted-by":"publisher","DOI":"10.1172\/JCI153604","volume":"132","author":"R Zhenhua","year":"2022","unstructured":"Zhenhua R, Anli Z, Zhichen S, Yong L, Jianfeng Y, Jian Q, et al. Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity. J Clin Investig. 2022;132(3):e153604. https:\/\/doi.org\/10.1172\/JCI153604.","journal-title":"J Clin Investig"},{"issue":"3","key":"769_CR62","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/1078-0432.CCR-15-1631","volume":"22","author":"DH Charych","year":"2016","unstructured":"Charych DH, Hoch U, Langowski JL, Lee SR, Addepalli MK, Kirk PB, et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin Cancer Res. 2016;22(3):680\u201390. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1631.","journal-title":"Clin Cancer Res"},{"key":"769_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24987-9","volume":"12","author":"J Ptacin","year":"2021","unstructured":"Ptacin J, Caffaro C, Ma L, Gall KMSJ, Aerni H, Acuff N, et al. An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism. Nat Commun. 2021;12:4785. https:\/\/doi.org\/10.1038\/s41467-021-24987-9.","journal-title":"Nat Commun"},{"issue":"10","key":"769_CR64","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","volume":"22","author":"R Hernandez","year":"2022","unstructured":"Hernandez R, Pder J, Laporte KM, Malek T. Engineering IL-2 for immunotherapy of autoimmunity and cancer. Nat Rev Immunol. 2022;22(10):614\u201328. https:\/\/doi.org\/10.1038\/s41577-022-00680-w.","journal-title":"Nat Rev Immunol"},{"key":"769_CR65","doi-asserted-by":"publisher","unstructured":"Klein C, Waldhauer I, Nicolini V, Freimoser-Grundschober A, Nayak T, Vugts D, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology. 2017;6(3):e1277306. https:\/\/doi.org\/10.1080\/2162402x.2016.1277306.","DOI":"10.1080\/2162402x.2016.1277306"},{"issue":"7930","key":"769_CR66","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","volume":"610","author":"LC Deak","year":"2022","unstructured":"Deak LC, Nicolini V, Hashimoto M, Karagianni M, Schwalie PC, Lauener L, et al. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells. Nature. 2022;610(7930):161\u201372. https:\/\/doi.org\/10.1038\/s41586-022-05192-0.","journal-title":"Nature"},{"issue":"1","key":"769_CR67","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.immuni.2022.12.006","volume":"56","author":"M Tichet","year":"2023","unstructured":"Tichet M, Wullschleger S, Chryplewicz A, Fournier N, Marcone R, Kauzlaric A, et al. Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T\u00a0cells and reprogramming macrophages. Immunity. 2023;56(1):162-179.e6. https:\/\/doi.org\/10.1016\/j.immuni.2022.12.006.","journal-title":"Immunity"},{"key":"769_CR68","doi-asserted-by":"publisher","unstructured":"Fusi I, Serger C, Herzig P, Germann M, Sandholzer MT, Oelgarth N, et al. PD-1\u2013targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer. Sci Transl Med. 2025;17(816):eadr3718. https:\/\/doi.org\/10.1126\/scitranslmed.adr3718.","DOI":"10.1126\/scitranslmed.adr3718"},{"key":"769_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1369376","volume":"15","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Chen C, Liu Y, Wang R, Feng C, Cai L, et al. A novel dual mechanism-of-action bispecific PD-1-IL-2v armed by a \u201c\u03b2\u03b3-only\u201d interleukin-2 variant. Front Immunol. 2024;15:1369376. https:\/\/doi.org\/10.3389\/fimmu.2024.1369376.","journal-title":"Front Immunol"},{"issue":"1","key":"769_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22980-w","volume":"12","author":"EJ Hsu","year":"2021","unstructured":"Hsu EJ, Cao X, Moon B, Bae J, Sun Z, Liu Z, et al. A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy. Nat Commun. 2021;12(1):2768. https:\/\/doi.org\/10.1038\/s41467-021-22980-w.","journal-title":"Nat Commun"},{"issue":"11","key":"769_CR71","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.it.2023.09.003","volume":"44","author":"V Niederlova","year":"2023","unstructured":"Niederlova V, Tsyklauri O, Kovar MSO. IL-2-driven CD8+T cell phenotypes: implications for immunotherapy. Trends Immunol. 2023;44(11):890\u2013901. https:\/\/doi.org\/10.1016\/j.it.2023.09.003.","journal-title":"Trends Immunol"},{"issue":"1","key":"769_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-025-00267-6","volume":"6","author":"Z Yan","year":"2025","unstructured":"Yan Z, Wang C, Wu J, Wang J, Ma T. TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives. Mol Biomed. 2025;6(1):27. https:\/\/doi.org\/10.1186\/s43556-025-00267-6.","journal-title":"Mol Biomed"},{"issue":"1","key":"769_CR73","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","volume":"12","author":"R Yang","year":"2021","unstructured":"Yang R, Sun L, Li CF, Wang YH, Yao J, Li H, et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun. 2021;12(1):832. https:\/\/doi.org\/10.1038\/s41467-021-21099-2.","journal-title":"Nat Commun"},{"issue":"7685","key":"769_CR74","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41586-021-03626-9","volume":"595","author":"KO Dixon","year":"2021","unstructured":"Dixon KO, Tabaka M, Schramm MA, Xiao S, Kuchroo VK. TIM-3 restrains anti-tumour immunity by regulating inflammasome activation. Nature. 2021;595(7685):101\u20136. https:\/\/doi.org\/10.1038\/s41586-021-03626-9.","journal-title":"Nature"},{"key":"769_CR75","doi-asserted-by":"publisher","unstructured":"Zhang Y, Ma C, Wang J, Ji X, Wu X, Jia Z, et al. Tim-3 negatively regulates IL-12 expression by monocytes in HCV infection. PLoS ONE. 2011;6(5):e19664. https:\/\/doi.org\/10.1371\/journal.pone.0019664.","DOI":"10.1371\/journal.pone.0019664"},{"key":"769_CR76","doi-asserted-by":"publisher","unstructured":"Chen C, Zhao F, Peng J, Zhao D, Xu L, Li H, et al. Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8+ T cell exhaustion and anti-PD-1 resistance. Cell Rep Med. 2024;5(8):101686. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101686.","DOI":"10.1016\/j.xcrm.2024.101686"},{"key":"769_CR77","doi-asserted-by":"publisher","unstructured":"Siddiqui I, Schaeuble K, Chennupati V, SA FM, S C-C, Pais Ferreira D, et al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity. 2019;50(1):195\u2013211. https:\/\/doi.org\/10.1016\/j.immuni.2018.12.021.","DOI":"10.1016\/j.immuni.2018.12.021"},{"issue":"78","key":"769_CR78","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ade5686","volume":"7","author":"S Gaggero","year":"2022","unstructured":"Gaggero S, Martinez-Fabregas J, Cozzani A, Fyfe P, Leprohon M, Yang J, et al. IL-2 is inactivated by the acidic pH environment of tumors enabling engineering of a pH-selective mutein. Sci Immunol. 2022;7(78):eade5686. https:\/\/doi.org\/10.1126\/sciimmunol.ade5686.","journal-title":"Sci Immunol"},{"issue":"1","key":"769_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60463-4","volume":"16","author":"X Zhang","year":"2025","unstructured":"Zhang X, Gao Y, Liao H, Wang W, Yang Z, Cao W, et al. TIM3-blockade synergizes with IL2 in alleviating intra-tumoral CD8+ T cell exhaustion. Nat Commun. 2025;16(1):5130. https:\/\/doi.org\/10.1038\/s41467-025-60463-4.","journal-title":"Nat Commun"},{"issue":"7","key":"769_CR80","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1158\/2159-8290.CD-23-1266","volume":"14","author":"KD Moynihan","year":"2024","unstructured":"Moynihan KD, Kumar MP, Sultan H, Pappas DC, Park T, Chin SM, et al. IL2 targeted to CD8+ T cells promotes robust effector T-cell responses and potent antitumor immunity. Cancer Discov. 2024;14(7):1206\u201325. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-1266.","journal-title":"Cancer Discov"},{"issue":"8","key":"769_CR81","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1158\/1078-0432.CCR-19-3354","volume":"26","author":"SN Quayle","year":"2020","unstructured":"Quayle SN, Girgis N, Thapa DR, Merazga Z, Kemp MM, Histed A, et al. CUE-101, a novel E7-pHLA-IL2-Fc fusion protein, enhances tumor antigen-specific T-cell activation for the treatment of HPV16-driven malignancies. Clin Cancer Res. 2020;26(8):1953\u201364. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3354.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"769_CR82","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","volume":"116","author":"T Kamada","year":"2019","unstructured":"Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, et al. PD-1\u00a0+\u00a0regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci USA. 2019;116(20):9999\u201310008. https:\/\/doi.org\/10.1073\/pnas.1822001116.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"769_CR83","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","volume":"40","author":"S Kumagai","year":"2022","unstructured":"Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin Y-t, Togashi Y, et al. Lactic acid promotes PD-1 expression in regulatory T\u00a0cells in highly glycolytic tumor microenvironments. Cancer Cell. 2022;40(2):201-218.e9. https:\/\/doi.org\/10.1016\/j.ccell.2022.01.001.","journal-title":"Cancer Cell"},{"issue":"16","key":"769_CR84","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e14505","volume":"42","author":"G Wu","year":"2024","unstructured":"Wu G, Ju D, Su Y, Yu H. Dose escalation of KY-0118, PD-1, and IL-2v due-target fusion protein in patients with advanced renal clear cell carcinoma, urothelial carcinoma, and malignant melanoma. J Clin Oncol. 2024;42(16):e14505. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e14505.","journal-title":"J Clin Oncol"},{"key":"769_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1537466","volume":"16","author":"F Ye","year":"2025","unstructured":"Ye F, Huang J, Cheng X, Chen SC, Huang F, Huang W-C, et al. AWT020: a novel fusion protein harnessing PD-1 blockade and selective IL-2 Cis-activation for enhanced anti-tumor immunity and diminished toxicity. Front Immunol. 2025;16:1537466. https:\/\/doi.org\/10.3389\/fimmu.2025.1537466.","journal-title":"Front Immunol"},{"key":"769_CR86","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011905","author":"P Murer","year":"2025","unstructured":"Murer P, Petersen L, Egli N, Salazar U, Neubert P, Zurbach A, et al. ANV600 is a novel PD-1 targeted IL-2R\u03b2\u03b3 agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2025-011905.","journal-title":"J Immunother Cancer"},{"issue":"16_suppl","key":"769_CR87","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e14506","volume":"43","author":"A Tamir","year":"2025","unstructured":"Tamir A, Eraslan RN, O\u2019Mara E, Kumar G, Shuparski A, Ruppova K, et al. Multiomic evaluation of TEV-56278, a PD-1-targeted attenuated IL-2 molecule, in a human ex vivo tumor model and association with immune activation with enhanced effector CD8 T cell selectivity. J Clin Oncol. 2025;43(16_suppl):e14506. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e14506.","journal-title":"J Clin Oncol"},{"issue":"10","key":"769_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101747","volume":"5","author":"J Wu","year":"2024","unstructured":"Wu J, Bloch N, Chang AY, Bhavsar R, Wang Q, Crawford A, et al. A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2R\u03b1 strengthens T cell-mediated anti-tumor therapies. Cell Rep Med. 2024;5(10):101747. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101747.","journal-title":"Cell Rep Med"},{"issue":"16_suppl","key":"769_CR89","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.104","volume":"43","author":"Z Lin","year":"2025","unstructured":"Lin Z, Bai X, Liang X, Chen Y, Wang H, Wang Y, et al. Efficacy and safety of IBI363 monotherapy or in combination with bevacizumab in patients with advanced colorectal cancer. J Clin Oncol. 2025;43(16_suppl):104. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.104.","journal-title":"J Clin Oncol"},{"key":"769_CR90","doi-asserted-by":"publisher","unstructured":"Lian B, Chen Y, Wang H, Zhang W, Zhang X, Fang M, et al. 1502 Efficacy and safety results of a first-in-class PD-1\/IL-2 \u03b1-bias bispecific antibody fusion protein IBI363 in patients (pts) with immunotherapy-treated, advanced acral and mucosal melanoma. J Clin Oncol. 2025;43(16_suppl):2502. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.2502.","DOI":"10.1200\/JCO.2025.43.16_suppl.2502"},{"issue":"16_suppl","key":"769_CR91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e14500","volume":"43","author":"J Coward","year":"2025","unstructured":"Coward J, Kichenadasse G, Voskoboynik M, Frentzas S, Cheng X, Liu E, et al. First-in-human study of AWT020, a bifunctional anti-PD-1\/IL-2 fusion protein, in patients with advanced cancer. J Clin Oncol. 2025;43(16_suppl):e14500. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e14500.","journal-title":"J Clin Oncol"},{"key":"769_CR92","doi-asserted-by":"publisher","unstructured":"Coward J, Kichenadasse G, Voskoboynik M, Frentzas S, Liu E, Cheng L, et al. 595Preliminary results of safety and antitumor activity from a first-in-human phase 1 study of AWT020, a bifunctional anti-PD-1\/IL-2 fusion protein, in patients with advanced tumors. J Immunother Cancer. 2025;13(Suppl 2):A676. https:\/\/doi.org\/10.1136\/jitc-2025-SITC2025.0595.","DOI":"10.1136\/jitc-2025-SITC2025.0595"},{"issue":"Suppl 2","key":"769_CR93","doi-asserted-by":"publisher","first-page":"A905","DOI":"10.1136\/jitc-2024-SITC2024.0800","volume":"12","author":"OI Cohen","year":"2024","unstructured":"Cohen OI, Rudnick-Glick S, Azoulay IS, Fine T, Elyada E, Radomir L, et al. 800 Preclinical in vivo characterization of the anti-tumor activity of a non-blocking PD-1 antibody fused to attenuated IL-2. J Immunother Cancer. 2024;12(Suppl 2):A905. https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.0800.","journal-title":"J Immunother Cancer"},{"issue":"Suppl 2","key":"769_CR94","doi-asserted-by":"publisher","first-page":"A769","DOI":"10.1136\/jitc-2024-SITC2024.0671","volume":"12","author":"JJ Luke","year":"2024","unstructured":"Luke JJ, Siu LL, Sznol M, Shalit Y, Weaver J, Jankovic V, et al. 671A first-in-human study evaluating safety, tolerability and efficacy of TEV-56278, as monotherapy and in combination with pembrolizumab in participants with locally advanced or metastatic solid tumors. J Immunother Cancer. 2024;12(Suppl 2):A769\u201370. https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.0671.","journal-title":"J Immunother Cancer"},{"issue":"Suppl 2","key":"769_CR95","doi-asserted-by":"publisher","first-page":"A1683","DOI":"10.1136\/jitc-2024-SITC2024.0967","volume":"12","author":"Z Li","year":"2024","unstructured":"Li Z, Zhang F, Zhang Z, Zhou H. 967 PTX912, a first-in-class PD-1\/proIL-2 fusion protein, exhibits PD-1 blockade and tumor activated IL-2R agonism for effective cancer immunotherapy with enhanced therapeutic window. Immuno Ther Cancer. 2024;12(Suppl 2):A1683. https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.0967.","journal-title":"Immuno Ther Cancer"},{"issue":"7","key":"769_CR96","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/ijc.34281","volume":"152","author":"Y Peng","year":"2023","unstructured":"Peng Y, Tao Y, Zhang Y, Wang J, Yang J, Wang Y. CD25: a potential tumor therapeutic target. Int J Cancer. 2023;152(7):1290\u2013303. https:\/\/doi.org\/10.1002\/ijc.34281.","journal-title":"Int J Cancer"},{"issue":"1","key":"769_CR97","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12876-023-02798-0","volume":"23","author":"J Qiu","year":"2023","unstructured":"Qiu J, Shi W, Zhang J, Gao Q, Feng L, Zhuang Z. Peripheral CD4+CD25hiCD127low regulatory T cells are increased in patients with gastrointestinal cancer. BMC Gastroenterol. 2023;23(1):168. https:\/\/doi.org\/10.1186\/s12876-023-02798-0.","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"769_CR98","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s12016-016-8590-3","volume":"52","author":"Y Shu","year":"2017","unstructured":"Shu Y, Hu Q, Long H, Chang C, Xiao R. Epigenetic variability of CD4+CD25+ Tregs contributes to the pathogenesis of autoimmune diseases. Clin Rev Allergy Immunol. 2017;52(2):260\u201372. https:\/\/doi.org\/10.1007\/s12016-016-8590-3.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"769_CR99","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.immuni.2024.02.001","volume":"57","author":"AN Shouse","year":"2024","unstructured":"Shouse AN, Laporte KM, Malek TR. Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer. Immunity. 2024;57(3):414\u201328. https:\/\/doi.org\/10.1016\/j.immuni.2024.02.001.","journal-title":"Immunity"},{"issue":"8095","key":"769_CR100","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41586-025-09440-x","volume":"649","author":"JL Hor","year":"2026","unstructured":"Hor JL, Schrom EC, Wong-Rolle A, Vistain L, Shang W, Dong Q, et al. Inhibitory PD-1 axis maintains high-avidity stem-like CD8+ T cells. Nature. 2026;649(8095):194\u2013204. https:\/\/doi.org\/10.1038\/s41586-025-09440-x.","journal-title":"Nature"},{"key":"769_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2025.08.008","volume":"7","author":"S Li","year":"2025","unstructured":"Li S, Yu S, Wang M, Zhang B, Xu Y. Synergistic potential of PD-1 blockade and IL-2 in cancer therapy via targeted bi-functional molecule design. Sci Bull (Beijing). 2025;7:S2095-9273(25)00809-6. https:\/\/doi.org\/10.1016\/j.scib.2025.08.008.","journal-title":"Sci Bull (Beijing)"},{"issue":"1","key":"769_CR102","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12964-024-01711-w","volume":"22","author":"M Yang","year":"2024","unstructured":"Yang M, Cui M, Sun Y, Liu S, Jiang W. Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance. Cell Commun Signal. 2024;22(1):338. https:\/\/doi.org\/10.1186\/s12964-024-01711-w.","journal-title":"Cell Commun Signal"},{"key":"769_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1583044","volume":"16","author":"L Cao","year":"2025","unstructured":"Cao L, Leclercq-Cohen G, Klein C, Sorrentino A, Bacac M. Mechanistic insights into resistance mechanisms to T cell engagers. Front Immunol. 2025;16:1583044. https:\/\/doi.org\/10.3389\/fimmu.2025.1583044.","journal-title":"Front Immunol"},{"issue":"1","key":"769_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01800-3","volume":"22","author":"X Chu","year":"2023","unstructured":"Chu X, Tian W, Wang Z, Zhang J, Zhou R. Co-inhibition of TIGIT and PD-1\/PD-L1 in cancer immunotherapy: mechanisms and clinical trials. Mol Cancer. 2023;22(1):93. https:\/\/doi.org\/10.1186\/s12943-023-01800-3.","journal-title":"Mol Cancer"},{"issue":"2","key":"769_CR105","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ccell.2025.01.001","volume":"43","author":"X Guo","year":"2025","unstructured":"Guo X, Nie H, Zhang W, Li J, Ge J, Xie B, et al. Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer. Cancer Cell. 2025;43(2):248\u201368. https:\/\/doi.org\/10.1016\/j.ccell.2025.01.001.","journal-title":"Cancer Cell"},{"issue":"11","key":"769_CR106","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ccell.2021.10.001","volume":"39","author":"L Au","year":"2021","unstructured":"Au L, Hatipoglu E, de Robert Massy M, Litchfield K, Beattie G, Rowan A, et al. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell. 2021;39(11):1497-1518.e11. https:\/\/doi.org\/10.1016\/j.ccell.2021.10.001.","journal-title":"Cancer Cell"},{"key":"769_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091408","author":"V Mc Neil","year":"2025","unstructured":"Mc Neil V, Lee SW. Advancing cancer treatment: a review of immune checkpoint inhibitors and combination strategies. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17091408.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"769_CR108","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.ijrobp.2024.01.010","volume":"118","author":"S Jabbour","year":"2024","unstructured":"Jabbour S, Kumar R, Anderson B, Chino J, Jethwa K, McDowell L, et al. Combinatorial approaches for chemotherapies and targeted therapies with radiation: united efforts to innovate in patient care. Int J Radiat Oncol Biol Phys. 2024;118(5):1240\u201361. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.01.010.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"769_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115593","volume":"226","author":"A Glasmacher","year":"2025","unstructured":"Glasmacher A, Garralda E, Gwaltney C, Rupalla K, Li C, Weber H. Dose optimization in cancer drug development: review and outcome of a multi-stakeholder workshop. Eur J Cancer. 2025;226:115593. https:\/\/doi.org\/10.1016\/j.ejca.2025.115593.","journal-title":"Eur J Cancer"},{"issue":"1","key":"769_CR110","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41392-024-01823-2","volume":"9","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y, et al. Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal Transduct Target Ther. 2024;9(1):132. https:\/\/doi.org\/10.1038\/s41392-024-01823-2.","journal-title":"Signal Transduct Target Ther"},{"key":"769_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1483454","volume":"14","author":"X Yin","year":"2024","unstructured":"Yin X, Song Y, Deng W, Blake N, Luo X, Meng J. Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy. Front Oncol. 2024;14:1483454. https:\/\/doi.org\/10.3389\/fonc.2024.1483454.","journal-title":"Front Oncol"},{"issue":"6","key":"769_CR112","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s43018-025-00986-3","volume":"6","author":"K Aliazis","year":"2025","unstructured":"Aliazis K, Christofides A, Shah R, Yeo YY, Jiang S, Charest A, et al. The tumor microenvironment\u2019s role in the response to immune checkpoint blockade. Nat Cancer. 2025;6(6):924\u201337. https:\/\/doi.org\/10.1038\/s43018-025-00986-3.","journal-title":"Nat Cancer"},{"issue":"11","key":"769_CR113","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1080\/09553002.2020.1820607","volume":"96","author":"W Cuiju","year":"2020","unstructured":"Cuiju W, Shibiao S, Ying T, Rongzong L, Haijuan X, Huifeng C, et al. IL-2 and IL-2R gene polymorphisms and immune function in people residing in areas with high background radiation, Yangjiang, China. Int J Radiat Biol. 2020;96(11):1466\u201372. https:\/\/doi.org\/10.1080\/09553002.2020.1820607.","journal-title":"Int J Radiat Biol"},{"issue":"17","key":"769_CR114","doi-asserted-by":"publisher","first-page":"9414","DOI":"10.3390\/ijms22179414","volume":"22","author":"H An","year":"2021","unstructured":"An H, Chon H, Kim C. Peripheral blood-based biomarkers for immune checkpoint inhibitors. Int J Mol Sci. 2021;22(17):9414. https:\/\/doi.org\/10.3390\/ijms22179414.","journal-title":"Int J Mol Sci"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00769-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00769-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00769-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:46:39Z","timestamp":1779795999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00769-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":114,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["769"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00769-x","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"11 February 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chang Xu, Tingxu Yan, Shuo Wen, Can Wu, Tingmin Chang, Eryan Kong, and Huicong Liu declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data, Code Availability"}},{"value":"Huicong Liu, Eryan Kong and Tingmin Chang contributed to the conception of the review. The manuscript was written by Chang Xu and Tingxu Yan. The pictures and tables were prepared by Shuo Wen and Can Wu. All authors read and approved the final manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}